U 88999E

Drug Profile

U 88999E

Latest Information Update: 10 Sep 1997

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer Nonindustrial source; Pharmacia Corporation
  • Class Antihypertensives
  • Mechanism of Action Calcium channel antagonists; Endothelin receptor antagonists; Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebrovascular disorders

Most Recent Events

  • 10 Sep 1997 No-Development-Reported for Cerebrovascular disorders in Japan (Unknown route)
  • 10 Sep 1997 No-Development-Reported for Cerebrovascular disorders in USA (Unknown route)
  • 31 Aug 1995 An in vitro study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top